Platform Architecture

The Orchestra

LurexBio's technology stack ``the orchestra``, represents a unified approach to immune engineering. Each platform—NeoTag™, Atraxis™, Atraxis-X™, and DeltaGate Logic™—addresses a distinct layer of immune activation, from tumor tagging and membrane fusion to adaptive signal control. Together, these platforms form a modular architecture that transforms immune-silent tumors into visible, targetable cells while maintaining precision, safety, and scalability across multiple disease categories.

How Our Platforms Work

A unified system of next-generation technologies that redefines how the immune system sees and responds to disease — with broad potential across oncology, autoimmune, and other immune-driven conditions. The adaptive delivery architecture also offers opportunities for collaboration and licensing, enabling precision delivery of therapeutic agents across the biotech and pharmaceutical landscape.

  • 01.
    Synthetic Immune Signals

    NeoTag™ is designed to apply engineered immune markers that enable immune-silent tumor cells to become visible to the body's defenses.

  • 02.
    Precision Delivery

    The Atraxis™, Atraxis-X™, and DeltaGate Logic™ platforms are designed to coordinate precision-timed therapeutic engagement, enabling controlled activation within cold tumor environments while safeguarding healthy tissue.

  • 03.
    Immune Activation

    DeltaGate Logic™ is designed to orchestrate precision immune engagement, restoring targeted immune awareness against tumors that evade detection.

NeoTag™ (Phase I)

Non-Genetic Immune Tagging

NeoTag™ (Phase I) decorates tumor cell surfaces with recognizable, pathogen‑based immune flags. By engaging the body’s existing immune memory, NeoTag™ enables tumor recognition. The approach is surface‑only, non‑genetic, and designed for repeat dosing across multiple targets.

Hot Tumor

Recognized by immune system with NeoTag™

Cold Tumor

Invisible to the immune system

Hot Tumor

Recognized by immune system with NeoTag™

Atraxis™ searching for Hot Tumors

Atraxis

Atraxis™ targets flagged hot tumors and delivers special payloads

Atraxis™ (Phase II)

Fusogenic Vesicle Delivery

Atraxis™ (Phase II) fuses with tumor cells to deliver immune signals or therapeutic payloads once the target is identified. Payloads are delivered directly—avoiding cellular breakdown and enabling precise surface or intracellular action. The system supports modular targeting ligands and customizable immune signal sets.